Targeted Therapy in Nonmelanoma Skin Cancers

Cancers

Giulia Spallone¹  Elisabetta Botti¹ 

[1] Department of Dermatology, University of Rome “Tor Vergata”, Via Montpellier 1, 00199, Rome, Italy;

关键词: basal cell carcinoma (BCC);    squamous cell carcinoma (SCC);    EGFR;    SMO inhibitor;    COX2;   

DOI  :  10.3390/cancers3022255

来源: mdpi

【 摘 要 】

Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.